Early oral switch to combined cefixime therapy for management of osteoarticular infections in pediatric sickle cell disease patients: A descriptive analysis
Background: The treatment of osteoarticular infections in pediatric patients with sickle cell disease (SCD) is a challenging task for the practitioner. The aim of this study is to evaluate cefixime for the treatment of osteoarticular infections in pediatric SCD patients by retrospective design. Meth...
Guardado en:
| Autores principales: | , , , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Elsevier
2022
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/97da5a1535124f5bb4dcb2f37236bc1f |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:97da5a1535124f5bb4dcb2f37236bc1f |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:97da5a1535124f5bb4dcb2f37236bc1f2021-11-30T04:14:44ZEarly oral switch to combined cefixime therapy for management of osteoarticular infections in pediatric sickle cell disease patients: A descriptive analysis1876-034110.1016/j.jiph.2021.11.006https://doaj.org/article/97da5a1535124f5bb4dcb2f37236bc1f2022-01-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S1876034121003695https://doaj.org/toc/1876-0341Background: The treatment of osteoarticular infections in pediatric patients with sickle cell disease (SCD) is a challenging task for the practitioner. The aim of this study is to evaluate cefixime for the treatment of osteoarticular infections in pediatric SCD patients by retrospective design. Methods: This study was done in the pediatric hospital of King Saud Medical City, Riyadh, Saudi Arabia. The data was obtained from medical records of patients aged 1–16 years admitted between January 2019 to December 2020, diagnosed with SCD and received cefixime for the treatment of OI. A descriptive study for pediatric patients admitted between January 2019 to December 2020 diagnosed with sickle cell disease and diagnosed with osteoarticular infection. All patients were treated with cefixime. Medians and interquartile ranges (IQRs) were used for the descriptive analysis. Results: A total of 260 patients were screened, and 51 cases [osteomyelitis (OM), n = 43, and septic arthritis (SA), n = 8] met the inclusion criteria. The median age of OM patients was 7 years, with males making up 67.4% of the cohort. The median length of IV antibiotics and hospital stays were 10 days and 11 days, respectively. The median total duration of antibiotic use was 37 and 25 days for OM and SA, respectively. The treatment success rate was 88% in OM cases and 100% in SA patients. Readmission was noted in 39.5% of the OM patients, while only 25% of the SA patients were recorded for reinfection. Conclusion: The study's findings revealed that Cefixime is a viable oral alternative for treating osteoarticular infection in pediatric SCD patients. Nonetheless, a prospective investigation is required to corroborate the findings of this study.Yahya A. MohzariRenad AlshuraimSyed Mohammed Basheeruddin AsdaqFahad AljobairAhmed AlrashedYazed Saleh AlsowaidaAmnah AlamerManea Fares Al MunjemMohammed I. Al MusawaMuhannad HatataMeshal A. AlzaaqiAljawharah BinrokanSaleh Ahmad AlajlanIvo AbrahamAhmad AlamerElsevierarticleCefiximeSickle cell diseasePediatricOsteoarticularOsteomyelitisSeptic arthritisInfectious and parasitic diseasesRC109-216Public aspects of medicineRA1-1270ENJournal of Infection and Public Health, Vol 15, Iss 1, Pp 1-6 (2022) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Cefixime Sickle cell disease Pediatric Osteoarticular Osteomyelitis Septic arthritis Infectious and parasitic diseases RC109-216 Public aspects of medicine RA1-1270 |
| spellingShingle |
Cefixime Sickle cell disease Pediatric Osteoarticular Osteomyelitis Septic arthritis Infectious and parasitic diseases RC109-216 Public aspects of medicine RA1-1270 Yahya A. Mohzari Renad Alshuraim Syed Mohammed Basheeruddin Asdaq Fahad Aljobair Ahmed Alrashed Yazed Saleh Alsowaida Amnah Alamer Manea Fares Al Munjem Mohammed I. Al Musawa Muhannad Hatata Meshal A. Alzaaqi Aljawharah Binrokan Saleh Ahmad Alajlan Ivo Abraham Ahmad Alamer Early oral switch to combined cefixime therapy for management of osteoarticular infections in pediatric sickle cell disease patients: A descriptive analysis |
| description |
Background: The treatment of osteoarticular infections in pediatric patients with sickle cell disease (SCD) is a challenging task for the practitioner. The aim of this study is to evaluate cefixime for the treatment of osteoarticular infections in pediatric SCD patients by retrospective design. Methods: This study was done in the pediatric hospital of King Saud Medical City, Riyadh, Saudi Arabia. The data was obtained from medical records of patients aged 1–16 years admitted between January 2019 to December 2020, diagnosed with SCD and received cefixime for the treatment of OI. A descriptive study for pediatric patients admitted between January 2019 to December 2020 diagnosed with sickle cell disease and diagnosed with osteoarticular infection. All patients were treated with cefixime. Medians and interquartile ranges (IQRs) were used for the descriptive analysis. Results: A total of 260 patients were screened, and 51 cases [osteomyelitis (OM), n = 43, and septic arthritis (SA), n = 8] met the inclusion criteria. The median age of OM patients was 7 years, with males making up 67.4% of the cohort. The median length of IV antibiotics and hospital stays were 10 days and 11 days, respectively. The median total duration of antibiotic use was 37 and 25 days for OM and SA, respectively. The treatment success rate was 88% in OM cases and 100% in SA patients. Readmission was noted in 39.5% of the OM patients, while only 25% of the SA patients were recorded for reinfection. Conclusion: The study's findings revealed that Cefixime is a viable oral alternative for treating osteoarticular infection in pediatric SCD patients. Nonetheless, a prospective investigation is required to corroborate the findings of this study. |
| format |
article |
| author |
Yahya A. Mohzari Renad Alshuraim Syed Mohammed Basheeruddin Asdaq Fahad Aljobair Ahmed Alrashed Yazed Saleh Alsowaida Amnah Alamer Manea Fares Al Munjem Mohammed I. Al Musawa Muhannad Hatata Meshal A. Alzaaqi Aljawharah Binrokan Saleh Ahmad Alajlan Ivo Abraham Ahmad Alamer |
| author_facet |
Yahya A. Mohzari Renad Alshuraim Syed Mohammed Basheeruddin Asdaq Fahad Aljobair Ahmed Alrashed Yazed Saleh Alsowaida Amnah Alamer Manea Fares Al Munjem Mohammed I. Al Musawa Muhannad Hatata Meshal A. Alzaaqi Aljawharah Binrokan Saleh Ahmad Alajlan Ivo Abraham Ahmad Alamer |
| author_sort |
Yahya A. Mohzari |
| title |
Early oral switch to combined cefixime therapy for management of osteoarticular infections in pediatric sickle cell disease patients: A descriptive analysis |
| title_short |
Early oral switch to combined cefixime therapy for management of osteoarticular infections in pediatric sickle cell disease patients: A descriptive analysis |
| title_full |
Early oral switch to combined cefixime therapy for management of osteoarticular infections in pediatric sickle cell disease patients: A descriptive analysis |
| title_fullStr |
Early oral switch to combined cefixime therapy for management of osteoarticular infections in pediatric sickle cell disease patients: A descriptive analysis |
| title_full_unstemmed |
Early oral switch to combined cefixime therapy for management of osteoarticular infections in pediatric sickle cell disease patients: A descriptive analysis |
| title_sort |
early oral switch to combined cefixime therapy for management of osteoarticular infections in pediatric sickle cell disease patients: a descriptive analysis |
| publisher |
Elsevier |
| publishDate |
2022 |
| url |
https://doaj.org/article/97da5a1535124f5bb4dcb2f37236bc1f |
| work_keys_str_mv |
AT yahyaamohzari earlyoralswitchtocombinedcefiximetherapyformanagementofosteoarticularinfectionsinpediatricsicklecelldiseasepatientsadescriptiveanalysis AT renadalshuraim earlyoralswitchtocombinedcefiximetherapyformanagementofosteoarticularinfectionsinpediatricsicklecelldiseasepatientsadescriptiveanalysis AT syedmohammedbasheeruddinasdaq earlyoralswitchtocombinedcefiximetherapyformanagementofosteoarticularinfectionsinpediatricsicklecelldiseasepatientsadescriptiveanalysis AT fahadaljobair earlyoralswitchtocombinedcefiximetherapyformanagementofosteoarticularinfectionsinpediatricsicklecelldiseasepatientsadescriptiveanalysis AT ahmedalrashed earlyoralswitchtocombinedcefiximetherapyformanagementofosteoarticularinfectionsinpediatricsicklecelldiseasepatientsadescriptiveanalysis AT yazedsalehalsowaida earlyoralswitchtocombinedcefiximetherapyformanagementofosteoarticularinfectionsinpediatricsicklecelldiseasepatientsadescriptiveanalysis AT amnahalamer earlyoralswitchtocombinedcefiximetherapyformanagementofosteoarticularinfectionsinpediatricsicklecelldiseasepatientsadescriptiveanalysis AT maneafaresalmunjem earlyoralswitchtocombinedcefiximetherapyformanagementofosteoarticularinfectionsinpediatricsicklecelldiseasepatientsadescriptiveanalysis AT mohammedialmusawa earlyoralswitchtocombinedcefiximetherapyformanagementofosteoarticularinfectionsinpediatricsicklecelldiseasepatientsadescriptiveanalysis AT muhannadhatata earlyoralswitchtocombinedcefiximetherapyformanagementofosteoarticularinfectionsinpediatricsicklecelldiseasepatientsadescriptiveanalysis AT meshalaalzaaqi earlyoralswitchtocombinedcefiximetherapyformanagementofosteoarticularinfectionsinpediatricsicklecelldiseasepatientsadescriptiveanalysis AT aljawharahbinrokan earlyoralswitchtocombinedcefiximetherapyformanagementofosteoarticularinfectionsinpediatricsicklecelldiseasepatientsadescriptiveanalysis AT salehahmadalajlan earlyoralswitchtocombinedcefiximetherapyformanagementofosteoarticularinfectionsinpediatricsicklecelldiseasepatientsadescriptiveanalysis AT ivoabraham earlyoralswitchtocombinedcefiximetherapyformanagementofosteoarticularinfectionsinpediatricsicklecelldiseasepatientsadescriptiveanalysis AT ahmadalamer earlyoralswitchtocombinedcefiximetherapyformanagementofosteoarticularinfectionsinpediatricsicklecelldiseasepatientsadescriptiveanalysis |
| _version_ |
1718406820994744320 |